The addition of irinotecan (CPT-11)...

The addition of irinotecan (CPT-11) to a regimen of 5-fluorouracil/leucovorin (5-FU/LV) increased the median progression-free survival in metastatic colorectal cancer make subordinates by nearly 35%, according to the accrues era Phase 3 trial permanent funded by the European Organization for Research and Treatment of Cancer (Brussels, Belgium). The prospective, multicenter, randomized, non-blinded inquiry compared two different chemotherapy regimens, infusional 5-FU/LV and infusional 5-FU/LV plus irinotecan, in 430 exposes with metastatic cancer of the colon or rectum